Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (8939)	6/2/1998 8:41:00 PM
From: 4 - Bob	Read Replies (1) \| Respond to of 23519

VLAD, At the very least you are taking proactive steps, and providing this thread with additional points of view. It would be a shame to accept at face value all the negative spins on VVUS/Muse recently. For one thing, the new and refill script data of Muse before viagra hit the market suggest that Muse works effectively for part of the ED community. If Muse's success rate was a poor as the VA report implies, the refills would have tanked big time last year. Since they didn't, it speaks for itself. As time passes, both MUSE and viagra should fly or sink on their own merits. VVUS longs must not faint in the faces of the big bad wolves and give their shares away at this time. Who has the most to gain/lose if the stock falls to 7 or rises to 30, the Longs or the Shorts?